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Introduction: Vitamin D deficiency has been reported to be common in patients with rheumatoid arthritis (RA)
who have a higher prevalence of osteoporosis and hip fracture than healthy individuals. Genetic variants affecting
serum 25-hydroxyvitamin D (25(OH)D) concentration, an indicator of vitamin D status, were recently identified by
genome-wide association studies of Caucasian populations. The purpose of this study was to validate the
association and to test whether the serum 25(OH)D-linked genetic variants were associated with the occurrence
of hip fracture in Japanese RA patients.
Methods: DNA samples of 1,957 Japanese RA patients were obtained from the Institute of Rheumatology,
Rheumatoid Arthritis (IORRA) cohort DNA collection. First, five single nucleotide polymorphisms (SNPs) that were
reported to be associated with serum 25(OH)D concentration by genome-wide association studies were genotyped.
The SNPs that showed a significant association with serum 25(OH)D level in the cross-sectional study were used in the
longitudinal analysis of hip fracture risk. The genetic risk for hip fracture was determined by a multivariate Cox
proportional hazards model in 1,957 patients with a maximum follow-up of 10 years (median, 8 years).
Results: Multivariate linear regression analyses showed that rs2282679 in GC (the gene encoding group-specific
component (vitamin D binding protein)) locus was significantly associated with lower serum 25(OH)D concentration
(P = 8.1 × 10−5). A Cox proportional hazards model indicated that rs2282679 in GC was significantly associated with the
occurrence of hip fracture in a recessive model (hazard ratio (95% confidence interval) = 2.52 (1.05-6.05), P = 0.039).
Conclusions: A two-staged analysis demonstrated that rs2282679 in GC was associated with serum 25(OH)D
concentration and could be a risk factor for hip fracture in Japanese RA patients.* Correspondence: kikari@ior.twmu.ac.jp
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Vitamin D regulates calcium and phosphate homeostasis
and reportedly has other roles in human physiology [1,2].
Vitamin D deficiency is associated with the occurrence
of osteoporosis, autoimmune diseases, cardiovascular dis-
ease, type 1 and type 2 diabetes mellitus, and several types
of cancer [3-7]. Vitamin D also plays an important role in
the maintenance of the musculoskeletal system. It is po-
sitively associated with muscle strength and physical
performance, and is negatively associated with fall and
fracture risk [8-11].
Vitamin D deficiency has been reported to be common
in patients with rheumatoid arthritis (RA), and more
than 70% of Japanese patients with RA had vitamin D
deficiency [12,13]. Significant associations of vitamin D
deficiency were found with some independent clinical
risk factors: female gender, younger age, high disability
score in the Japanese version of the Health Assessment
Questionnaire (J-HAQ), low serum total protein level,
low serum total cholesterol level, high serum alkaline
phosphate (ALP) level, and use of non-steroidal anti-
inflammatory drugs (NSAIDs) [12].
Bone mineral density (BMD) is the major predictor of
osteoporotic fracture, and previous studies have reported
that patients with RA have a lower BMD and are
at greater risk of hip fracture than healthy individuals
[14,15]. We have previously shown that a high J-HAQ
disability score, advanced age, history of total knee re-
placement (TKR), and low body mass index (BMI) were
clinical risk factors for the occurrence of hip fracture in
Japanese patients with RA [16].
Prior twin and family studies suggested that genetic fac-
tors also influence serum vitamin D concentration [17,18].
Genetic variants that affect serum 25-hydroxyvitamin D
(25(OH)D) concentration, an indicator of vitamin D status,
were recently identified in a meta-analysis of genome-wide
association studies (GWAS) in Caucasian populations
[19,20]. Though the presence of heterogeneity in genes re-
lated to RA has been suggested in many population-based
studies [21], these associations remain unknown in the
Japanese population.
The purpose of this study was to validate the possible
association between genetic variants and serum 25(OH)
D concentration and to test whether the serum 25(OH)
D-linked variants were associated with the occurrence of
hip fracture in Japanese patients with RA.
Methods
Study population
This study was a part of the Institute of Rheumatology,
Rheumatoid Arthritis cohort study (IORRA), a single-
institution-based, large-scale prospective observational
cohort study with an enrollment of over 5,000 Japanese
patients with RA, began in 2000 [12,16,22]. DNAsamples of 1,957 Japanese RA patients were obtained
from the IORRA DNA collection. All the patients sa-
tisfied the American College of Rheumatology 1987
revised criteria for RA. Tokyo Women’s Medical University
Genome Ethics Committee approved the present study
and each individual signed an informed consent form after
receiving a verbal explanation of the study.SNP selection and genotyping
Five single nucleotide polymorphisms (SNPs) were selected
from the results of recent genome-wide association studies
(GWAS) that showed positive associations between serum
25(OH)D levels and the following: rs2282679 in the GC
(group-specific component) locus, rs3829251, rs12785878
and rs1790349 in the DHCR7/NADSYN1 (7-dehydro-
cholesterol reductase/nicotinamide-adenine dinucleotide
synthetase 1) locus, and rs10741657 in the CYP2R1 (cyto-
chrome P450, family 2, subfamily R, polypeptide 1) locus
[19,20]. Genotyping was performed by using the TaqMan
fluorogenic 5′ nuclease assay according to the manufac-
turer’s instructions (Applied Biosystems, Tokyo, Japan).
Duplicate samples and negative controls were included to
ensure accuracy of SNP genotyping. All polymerase chain
reactions were performed by using the GeneAmp PCR Sys-
tem 9700 (Applied Biosystems), and endpoint fluorescent
readings for TaqMan assays were done on an ABI PRISM
7900 HT Sequence Detection System (Applied Biosystems)
as described elsewhere [22].Measurement of serum 25(OH)D concentration
Serum 25(OH)D concentrations were measured in 899
of 1,957 patients from whom we obtained DNA sam-
ples. As vitamin D is synthesized in the skin under the
influence of sunlight and the seasonal variance in serum
levels of vitamin D is well known, serum samples
were collected in the same season, spring of 2011 [23].
The DiaSorin 25(OH)D125I radioimmunoassay kit was
used for quantitative determination of serum 25(OH)D
concentration.Assessment of hip fracture
The occurrence of hip fracture after enrollment in
IORRA was determined by the response to a patient
questionnaire every six months from October 2000 to
October 2010 with a maximum follow-up period of
10 years. The data were confirmed by review of medical
records and radiographs as described elsewhere [16].
Only the occurrence of the first hip fracture reported by
patients was included in this study. The occurrence of
hip fracture caused by major trauma such as car ac-
cidents was excluded. A total of 39 hip fractures in 39
patients were identified and included in this study.
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Stage 1: cross-sectional analyses of SNPs associated with
serum 25(OH)D concentration
A two-staged analysis was used. First, cross-sectional
associations were examined between serum 25(OH)D
concentrations and risk alleles of each SNP using multi-
variate linear regression analyses (adjusted for independ-
ent non-genetic risk factors) in 899 of the 1,957 patients.
The putative risk alleles were defined as the alleles that
are associated with lower serum 25(OH)D concentration
based on prior reports [19,20]. The number of risk alleles
for genotyped SNPs (0, 1 and 2) was used to test the ad-
ditive effect of the alleles on lower serum 25(OH)D con-
centration. The following factors that have been shown to
be significantly associated with lower serum 25(OH)D
levels were selected as independent non-genetic risk fac-
tors: gender, age, J-HAQ disability score, serum total pro-
tein level, serum total cholesterol level, serum ALP level,
and NSAID use [12].
Stage 2: longitudinal association analyses of SNPs
associated with occurrence of hip fracture
The SNP that showed a significant association with
serum 25(OH)D concentration was selected to test the
longitudinal association with the hip fracture event. The
length of time from the date of enrollment in IORRA to
the date of the occurrence of hip fracture was calculated.
A multivariate Cox proportional hazards model adjusted
for independent non-genetic risk factors that were asso-
ciated with hip fracture was performed in the cohort of
1,957 patients [16]. The following factors at the time of
hip fracture reported were used as the independent non-
genetic risk factors: J-HAQ disability score, age, history
of TKR, and BMI. The proportional hazards assumption
for the Cox model was assessed using log-minus-log
plots for survival analysis. All statistical analyses were
performed using the R software package [24].
Results
Clinical and demographic characteristics of the patients
Demographic, clinical and therapeutic data describing the
1,957 patients at the time of enrollment in IORRA are
shown in Table 1. In this cohort, serum 25(OH)D con-
centrations were measured in 899 patients in the spring of
2011 (Table 1). The median serum 25(OH)D concen-
tration was 15.30 ng/mL (IQR, 12.10 to 20.10). During a
maximum follow-up period of 10 years (median, 8.0 years;
IQR, 4.5 to 10.0 years) 39 hip fractures in 1,957 patients
were identified.
Genotyping
The overall genotyping success rate was 97.3% and the
genotype concordance rate was 100% as assessed by du-
plicate samples. After the application of quality controlcriteria for genotyping (removed samples that consis-
tently failed for >20% (1/5) of SNPs, removed SNPs with
a call rate <95% after removing samples that consis-
tently failed), 1,915 of the 1,957 samples and all poly-
morphisms were accepted for the analyses. The studied
polymorphisms were found to be in Hardy-Weinberg
equilibrium.
Stage 1: cross-sectional analyses of SNPs associated with
serum 25(OH)D concentration
A multivariate linear regression analysis adjusted for inde-
pendent non-genetic risk factors showed that the minor
allele of rs2282679 (= C) in GC was significantly associated
with lower serum 25(OH)D concentrations (P = 8.1 × 10−5,
Table 2). The median serum 25(OH)D concentrations
(ng/mL) for the genotypes of rs2282679 in GC were 16.1,
15.2 and 14.7, respectively for AA, AC and CC (Figure 1).
The other SNPs did not show a significant association. The
minor allele frequency of rs2282679 (GC) in RA patients
(= 0.259) did not differ significantly from a Japanese
control population (= 0.258, P = 0.98 by chi-squared test,
n = 752), which was obtained from the DNA collection of
the Pharma SNP Consortium, Tokyo, Japan, currently
entrusted to the Health Science Research Resources Bank,
Osaka, Japan, as described elsewhere [22].
Stage 2: longitudinal association analyses of SNPs
associated with occurrence of hip fracture
A multivariate Cox proportional hazards regression
model adjusted for the independent non-genetic risk fac-
tors indicated that homozygous for the risk allele of
rs2282679 in the GC locus regarding low serum 25(OH)
D concentration was significantly associated with the
occurrence of hip fracture (hazard ratio (95% CI) = 2.52
(1.05, 6.05), P = 0.039) (Table 3, Figure 2). The associa-
tion was still significant when the use of active vitamin
D or bisphosphonate were included in the analysis as in-
dependent variables. The proportion of patients treated
with active vitamin D or bisphosphonate did not differ
significantly between homozygous for the risk allele
of rs2282679 (CC) and the others (data not shown).
Supplemental results of the Cox regression analyses for
other SNPs that were not associated with serum 25(OH)
D concentration did not show a significant association
with the occurrence of hip fracture (Table 3, Figure 2).
Discussion
In this study, an association between a polymorphism of
rs2282679 in the GC locus and serum 25(OH)D con-
centration was validated in Japanese patients with RA.
Minor alleles of rs2282679 had additive effects on de-
creasing serum 25(OH)D concentrations. In addition,
rs2282679 was significantly associated with the occur-
rence of hip fracture in Japanese patients with RA. This
Table 1 Demographic, clinical and therapeutic data at the time of an enrollment in IORRA and at the time of
measurement of serum 25(OH)D concentration
Factor At the time of enrollment in IORRA (n = 1957) At the time of measurement of serum
25(OH)D concentration (spring 2011, n = 899)
Age, years 57.5 (49.5 to 64.6) 64.3 (56.7 to 70.6)
Sex, female 1668 (85.2) 766 (87.7)
Duration of disease, years 7.0 (2.0 to 14.0) 16.0 (11.0 to 23.0)
BMI, kg/m2 21.2 (19.4 to 23.3) 21.2 (19.2 to 23.2)
DAS28 4.2 (3.3 to 5.0) 3.0 (2.4 to 3.8)
J-HAQ 0.8 (0.2 to 1.4) 0.6 (0.1 to 0.8)
RF, positive 1531 (81.8) 698 (80.0)
History of smoking, ever 641 (34.5) 235 (28.4)
History of TKR, ever 85 (4.3) 178 (20.4)
DMARDs use, ever 1670 (85.3) 777 (89.0)
Methotrexate use, ever 792 (40.8) 638 (73.1)
Biologic use, ever 12 (0.6) 155 (17.8)
Corticosteroid use, ever 932 (47.6) 399 (45.7)
Bisphosphonate use, ever 63 (3.2) 280 (32.1)
Active vitamin D use, ever 61 (3.1) 112 (12.8)
Serum total protein level, g/dL Data not available 7.3 (7.0 to 7.6)
Serum total cholesterol level, mg/dL Data not available 209.0 (188.0 to 231.0)
Serum alkaline phosphate level, IU/L Data not available 258.0 (213.0 to 321.2)
NSAIDs use, ever Data not available 515 (59.0)
Data are presented as median (IQR) or n (%). IORRA, Institute of Rheumatology, Rheumatoid Arthritis cohort; BMI, body mass index; DAS28, disease activity score
in 28 joints; J-HAQ, Japanese version of the Health Assessment Questionnaire; RF, rheumatoid factor; TKR, total knee replacement; DMARD, disease modifying
antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug.
Table 2 Multivariate linear regression analyses of each
SNP associated with serum 25(OH)D concentration
Locus SNP MAF† β SE P-value
GC rs2282679 0.259 (A/C) −0.13 0.033 8.1 × 10−5
DHCR7/NADSYN1 rs3829251 0.375 (G/A) −0.0031 0.032 0.92
rs12785878 0.328 (G/T) 0.0057 0.032 0.86
rs1790349 0.361 (A/G) −0.016 0.032 0.63
CYP2R1 rs10741657 0.387 (G/A) 0.035 0.034 0.30
All analyses were adjusted for independent non-genetic risk factors: gender,
age, Japanese version of the Health Assessment Questionnaire disability score,
total protein level, total cholesterol level, alkaline phosphate level, and
non-steroidal anti-inflammatory drugs use [12]. †Alleles are listed as major
allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele
frequency; SE, standard error; GC, group-specific component; DHCR7/NADSYN1,
7-dehydrocholesterol reductase/nicotinamide-adenine dinucleotide synthetase
1; CYP2R1, cytochrome P450, family 2, subfamily R, polypeptide 1.
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sociated with the risk for hip fracture.
The GC gene encodes the group-specific component
known as the vitamin D binding protein (DBP) that plays
an important role in the vitamin D metabolic pathway
[25]. Most circulating vitamin D metabolites are bound to
DBP to be transported to target organs. In the previous
candidate gene studies and the recent GWAS, some GC
polymorphisms were associated with serum 25(OH)D
concentration, and the strongest association was observed
for rs2282679 [19,20,26]. Our results provide supportive
evidence that serum 25(OH)D concentration might partly
be affected by a polymorphism of rs2282679 or the other
variants that are in tight linkage disequilibrium with
rs2282679.
Vitamin D is an important factor in mineral metabo-
lism, bone growth and maintenance of the skeleton [1].
In addition, 1,25(OH)2D, one of the vitamin D metabo-
lites, has direct action on muscle strength and function
modulated by vitamin D receptors expressed in human
muscle tissue [8]. Therefore, vitamin D deficiency can
lead to low bone density and muscle weakness, resulting
in falls and fractures [8,27,28]. In many studies, vitaminD supplementation has been reported to reduce the risk
for falls and fractures among older individuals [29,30].
To date, many genetic factors associated with low-
trauma fracture including hip fracture have been reported
in genome-wide meta-analysis studies [31,32]. Many va-
riants with small effects may contribute to fracture risk,
but only a few vitamin D-related genetic polymorphisms
Figure 1 Boxplots representing the distribution of serum 25
(OH)D concentration according to the number of the risk allele
of rs2282679 (minor allele, C) in the GC locus. Each box
represents the IQR range of values, with the bold line showing the
median value. The vertical lines show maximum and minimum
values that fall within 1.5 box lengths, the open circles show
extreme values >1.5 box plot lengths.
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[33]. We explored the genetic risk of hip fracture in va-
riants demonstrated to be associated with lower serum
vitamin D concentration and found an association bet-
ween rs2282679 in GC and the occurrence of hip frac-
ture. Our results indicated that the risk allele carriers
of the GC gene polymorphism tend to have low vitamin
D levels that lead to greater risk of hip fracture.
Though DHCR7/NADSYN1 and CYP2R1 poly-
morphisms were associated with serum 25(OH)DTable 3 Hip fracture risk for rs2282679 (GC) and the
other SNPs adjusted for independent non-genetic risk
factors
Locus SNP HR 95% CI P-value
GC rs2282679 2.52 1.05, 6.05 0.039
DHCR7/NADSYN1 rs3829251 1.00 0.39, 2.56 1.00
rs12785878 0.71 0.22, 2.30 0.56
rs1790349 1.04 0.40, 2.65 0.94
CYP2R1 rs10741657 1.31 0.58, 3.02 0.51
All analyses were adjusted for independent non-genetic factors: Japanese
version of the Health Assessment Questionnaire disability score, age,
history of total knee replacement, and body mass index [16]. SNP, single
nucleotide polymorphism; HR, hazard ratio; GC, group-specific component;
DHCR7/NADSYN1, 7-dehydrocholesterol reductase/nicotinamide-adenine
dinucleotide synthetase 1; CYP2R1, cytochrome P450, family 2, subfamily R,
polypeptide 1.concentration in the recent GWAS, we could not val-
idate such an association in this study [19,20]. There
are a number of possible explanations for the lack of
an association. One is the insufficient statistical power
to validate the associations. The number of samples
was smaller than in the previous reports [20]. The SNP
with highest statistical power to validate the associ-
ation in this study was rs2282679 in the GC locus with
a value of 0.72, and the others had comparatively lower
statistical power (for example, 0.22 with rs3829251 in
the DHCR7/NADSYN1 locus). Another reason for the
lack of an association is that all studied subjects were
RA patients, whereas the recent GWAS were in
healthy individuals [19,20]. Vitamin D is related to im-
munological processes, and vitamin D status has been
reported to be associated with the risk of developing
autoimmune diseases including RA [1,14]. In addition,
serum vitamin D concentration has been shown to be
lower in patients with greater disease activity [34]. Al-
though the disease activity of the patients might affect
the results of this study, DAS28 was not associated
with serum 25(OH)D level in the studied population
(data not shown). The difference in the genetic back-
ground between Caucasian and Japanese populations
might also affect the results, which suggests genetic
heterogeneity in NADSYN1, DHCR7 and CYP2R1.
The strength of this study is that the datasets were
relatively large and based on a single-institution cohort
study of Japanese patients with RA. Serum 25(OH)D
concentration was measured in the same season of the
same year. Therefore, the differences between regions,
heterogeneity and seasons had less influence on the
results.
The potential limitation of this study is that the
serum 25(OH)D concentration data were available
from only 899 of the 1,957 patients with DNA samples,
and the study on serum 25(OH)D concentration was a
cross-sectional study. The smaller sample size reduced
the statistical power to detect minor effects on events.
Though the measurement from multiple time points
would provide more valid estimates of the results,
there was only one blood sample assayed for serum 25
(OH)D concentration for each person. Further studies
are required to confirm these associations.Conclusion
In conclusion, our data demonstrated that rs2282679
in GC was associated with both serum 25(OH)D
concentration and the occurrence of hip fracture in
Japanese patients with RA. These results might con-
tribute to a better understanding of the biological
impact of genetic variation within the vitamin D meta-
bolic pathway.
Figure 2 Cumulative incidence of hip fracture for patients who were homozygous or heterozygous for the non-risk allele and patients
homozygous for the risk allele of each single nucleotide polymorphism (analyzed by the Kaplan-Meier method). Homozygous for the
risk allele of rs2282679 (C) in the GC locus, a serum 25(OH)D-linked genetic variant, was significantly associated with the occurrence of
hip fracture.
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